DALLAS - Spectral AI, Inc. (NASDAQ:MDAI), a Dallas-based artificial intelligence company specializing in medical diagnostics, has received a new award exceeding $850,000 from the Medical Technology Enterprise Consortium (MTEC). This funding is set to further the development of the company's handheld predictive burn wound healing device, DeepView SnapShot M®, designed for battlefield assessments.
The DeepView SnapShot M® operates on Spectral AI's AI-driven DeepView™ System platform and aims to enhance the triage process by offering quick and accurate wound assessments. This allows medical personnel to prioritize treatment for severe burn injuries, which is crucial in combat zones and military hospitals.
The technology reflects MTEC's commitment to advancing prototypes that improve the health and performance of U.S. military service members. The consortium works in collaboration with the U.S. Army Medical Materiel Development Activity (USAMMDA), a key player in delivering medical solutions to the armed forces.
Peter M. Carlson, CEO of Spectral AI, expressed gratitude for the continued government support and emphasized the importance of clinician collaboration in refining the device. The DeepView SnapShot M® represents the broader capabilities of the DeepView™ System, which is designed to provide immediate, objective assessments of burn wounds' healing potential.
The DeepView™ System utilizes a multispectral imaging algorithm trained against a vast database of clinically validated data points, aiming to revolutionize wound care management by improving patient outcomes and reducing healthcare costs.
The recent award brings the total non-dilutive government funding for the product to over $7 million, underscoring the significant investment in the development of this medical technology.
This news is based on a press release statement from Spectral AI, Inc. The company is known for its work in predictive AI for medical diagnostics, focusing on wound care applications such as burns and diabetic foot ulcers. Spectral AI continues to develop its DeepView System with the goal of changing the current standard of care in wound management.
In other recent news, Spectral AI, Inc. has reported a significant expansion of its patent portfolio, a 24.6% increase in Research & Development revenue to $6.3 million, and an improved cash position of $10.2 million. It has also announced a collaboration with PolyNovo Limited for burn indication in Australia and the expansion of its clinical trial sites in the United States. Furthermore, the company has called for an investigation into potential illegal market manipulation of its stock. These are among the recent developments for Spectral AI, Inc., a company specializing in AI-driven medical diagnostics.
The company's patent portfolio, supporting its DeepView System, has grown by 30%, now totaling 26 patents. This growth is integral to the company's future commercialization initiatives. Meanwhile, Spectral AI has partnered with PolyNovo Limited to introduce the DeepView System in Australia, aiming to improve burn care.
Spectral AI's R&D revenue has seen a significant increase, and the company projects full-year 2024 R&D revenue to be approximately $28 million, marking a 55% year-over-year increase, according to an analysis by BTIG. The company has also expanded its clinical trial sites for the 2024 Burn Pivotal Study, adding the University of California San Diego and the University of Utah to its network.
In addition, Spectral AI has urged Nasdaq and state securities regulators in Florida, Louisiana, and Texas to investigate possible manipulative trading practices affecting its stock. The company's board member and largest shareholder, Erich Spangenberg, is leading this effort, highlighting the company's commitment to protecting shareholder interests.
InvestingPro Insights
As Spectral AI, Inc. (NASDAQ:MDAI) secures additional funding for its innovative DeepView SnapShot M® device, the financial landscape of the company offers a mixed picture. According to InvestingPro, Spectral AI is trading near its 52-week low, suggesting that the market may currently undervalue the company's stock. This is an important consideration for investors who are looking at the potential growth prospects of Spectral AI in the wake of its recent developments.
InvestingPro data highlights several key financial metrics for Spectral AI. The company's market capitalization stands at $24.82 million, indicating its size within the market. Despite a modest revenue growth of 0.3% over the last twelve months as of Q2 2024, the company's gross profit margin is relatively strong at 45.12%. However, it's important to note that Spectral AI is not currently profitable, with an operating income margin of -51.84% for the same period. These figures underscore the challenges the company faces in achieving profitability, which is also reflected in the InvestingPro Tip that analysts do not anticipate the company will be profitable this year.
InvestingPro also provides additional tips for those interested in a deeper dive into Spectral AI's financial health. For instance, the company operates with a moderate level of debt and does not pay dividends to shareholders, which may influence investment decisions. For those considering an investment in Spectral AI, it's worth noting that there are 6 additional InvestingPro Tips available, offering further insights into the company's financial performance and stock valuation.
With the company's recent government award and its focus on advancing medical technology for military use, Spectral AI's financials and market performance are crucial for stakeholders and potential investors. As the company continues to innovate in the medical diagnostics space, keeping an eye on these financial indicators will be key to understanding its future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.